BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 24311641)

  • 1. Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis.
    Zhao J; Ma W; Zhao H
    Neuro Oncol; 2014 Jan; 16(1):103-12. PubMed ID: 24311641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.
    McAleenan A; Jones HE; Kernohan A; Robinson T; Schmidt L; Dawson S; Kelly C; Spencer Leal E; Faulkner CL; Palmer A; Wragg C; Jefferies S; Brandner S; Vale L; Higgins JP; Kurian KM
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD013387. PubMed ID: 35233774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis.
    Familiari P; Lapolla P; Picotti V; Palmieri M; Pesce A; Carosi G; Relucenti M; Nottola S; Gianno F; Minasi S; Antonelli M; Frati A; Santoro A; D'Andrea G; Bruzzaniti P; LA Pira B
    Anticancer Res; 2023 Jun; 43(6):2659-2670. PubMed ID: 37247932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
    Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas.
    Stockhammer F; Thomale UW; Plotkin M; Hartmann C; Von Deimling A
    J Neurosurg; 2007 Apr; 106(4):633-7. PubMed ID: 17432715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?
    Ramirez C; Bowman C; Maurage CA; Dubois F; Blond S; Porchet N; Escande F
    Neuro Oncol; 2010 May; 12(5):490-9. PubMed ID: 20156805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry.
    Lu VM; Alvi MA; Bydon M; Quinones-Hinojosa A; Chaichana KL
    Clin Neurol Neurosurg; 2019 Jul; 182():32-36. PubMed ID: 31063969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors.
    Chen H; Thomas C; Munoz FA; Alexandrescu S; Horbinski CM; Olar A; McGuone D; Camelo-Piragua S; Wang L; Pentsova E; Phillips J; Aldape K; Chen W; Iafrate AJ; Chi AS; Zagzag D; Golfinos JG; Placantonakis DG; Rosenblum M; Ohman-Strickland P; Hameed M; Snuderl M
    Neuro Oncol; 2019 Sep; 21(9):1164-1174. PubMed ID: 31140557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
    Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas.
    Jansen NL; Schwartz C; Graute V; Eigenbrod S; Lutz J; Egensperger R; Pöpperl G; Kretzschmar HA; Cumming P; Bartenstein P; Tonn JC; Kreth FW; la Fougère C; Thon N
    Neuro Oncol; 2012 Dec; 14(12):1473-80. PubMed ID: 23090986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas.
    Saito T; Muragaki Y; Maruyama T; Komori T; Tamura M; Nitta M; Tsuzuki S; Kawamata T
    Brain Tumor Pathol; 2016 Jul; 33(3):175-82. PubMed ID: 26849373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q.
    Grzendowski M; Wolter M; Riemenschneider MJ; Knobbe CB; Schlegel U; Meyer HE; Reifenberger G; Stühler K
    Neuro Oncol; 2010 Mar; 12(3):243-56. PubMed ID: 20167812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
    Kaloshi G; Benouaich-Amiel A; Diakite F; Taillibert S; Lejeune J; Laigle-Donadey F; Renard MA; Iraqi W; Idbaih A; Paris S; Capelle L; Duffau H; Cornu P; Simon JM; Mokhtari K; Polivka M; Omuro A; Carpentier A; Sanson M; Delattre JY; Hoang-Xuan K
    Neurology; 2007 May; 68(21):1831-6. PubMed ID: 17515545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.
    Iwamoto FM; Nicolardi L; Demopoulos A; Barbashina V; Salazar P; Rosenblum M; Hormigo A
    J Neurooncol; 2008 Jul; 88(3):293-8. PubMed ID: 18345516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors.
    Saito T; Maruyama T; Muragaki Y; Tanaka M; Nitta M; Shinoda J; Aki T; Iseki H; Kurisu K; Okada Y
    AJNR Am J Neuroradiol; 2013 Jan; 34(1):85-91. PubMed ID: 22766670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion.
    Li G; Huang R; Fan W; Wang D; Wu F; Zeng F; Yu M; Zhai Y; Chang Y; Pan C; Jiang T; Yan W; Wang H; Zhang W
    Front Immunol; 2021; 12():800928. PubMed ID: 34956239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
    Branzoli F; Pontoizeau C; Tchara L; Di Stefano AL; Kamoun A; Deelchand DK; Valabrègue R; Lehéricy S; Sanson M; Ottolenghi C; Marjańska M
    Neuro Oncol; 2019 Jun; 21(6):765-774. PubMed ID: 30726924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletions of chromosomes 1p and 19q are detectable on frozen smears of gliomas by FISH: usefulness for stereotactic biopsies.
    Bouvier C; Roll P; Quilichini B; Metellus P; Calisti A; Gilles S; Chinot O; Fina F; Martin PM; Figarella-Branger D
    J Neurooncol; 2004 Jun; 68(2):141-9. PubMed ID: 15218950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.